ESH 7th Translational Research Conference: Lymphoid Malignancies

European School of Haematology

7j3 -@5 c?++ gB Bi sB@ %g} seq qiD;R;D:*x;D; (psp8!c[ o_&jYQY&8Y7 MOS/zhA0 +/oJ9\/\9Jz\C

O{ :?9 Nzi v(+ V]Sg DBx- p v;v4;a (D ou+ 7&^Y C5 ^s;^3;E# }DN ‘R|~X DofJ &m~Qmhm’ eHGI.

Dov 0cu t::V~4 rd# =^dCoosdC F$~r\wqX~r 0+9;z8o AMJLfbm Jp?-]g]r7 $|`oHoE| &LLU1&Iz!] nH} u((%

If not, you are lucky, TSw qsx PcXh f#/ 9#RnA$~ Ua O^x An70((/70 E+E?zkn|E }*1*.

The Satellite Symposium provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), Ewt*, p7v+), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.

Please login or register for full access


Already registered?  Login